Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2023-07-03 Earnings Release
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
Earnings Release Classification · 97% confidence The document is explicitly titled "Press Release" and announces clinical trial data presentation (NCX 470 Phase 3 Mont Blanc) at a scientific congress (World Glaucoma Congress). It provides key efficacy results, scientific context, and updates on future trials. This format, focusing on recent operational/scientific achievements rather than comprehensive annual financial statements (10-K) or mandatory regulatory filings, strongly suggests an Earnings Release (ER) or a general announcement. Since it details specific scientific findings and is presented as a press release announcing data, it aligns best with the 'Earnings Release' category, which often includes operational and scientific highlights, even if it's not strictly quarterly earnings figures. It is not a full transcript (CT), a formal annual report (10-K), or a proxy statement (DEF 14A). Given the context of presenting key data points, ER is the most appropriate fit among the options provided for a major operational update announced via press release. Q2 2023
2023-07-03 English
Nicox : Présentation au Congrès Mondial du Glaucome de données sur le NCX 470 provenant de l’étape adaptative de sélection de dose de l’étude de phase 3 Mont Blanc et d’une analyse de sous-groupes de
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and is dated July 3, 2023. It announces the presentation of data regarding the drug NCX 470 at the 10th World Glaucoma Congress (WGC). The content focuses on clinical trial results (Phase 3 Mont Blanc study) and scientific findings, which are typical components of an Investor Presentation (IP) or a general corporate/scientific update. Since it is a press release detailing scientific/clinical progress and presentation at a conference, it aligns best with the Investor Presentation (IP) category, which covers detailed information for investors on strategy and results, often disseminated via press release following scientific events. It is not a formal regulatory filing like 10-K, nor is it a short announcement of a report (RPA/RNS).
2023-07-03 French
Nicox: 2023 Ordinary Shareholder Meeting
AGM Information Classification · 99% confidence The document is explicitly titled "Nicox: 2023 Ordinary Shareholder Meeting" and discusses the failure to reach a quorum for a meeting scheduled for June 1st, and the rescheduling of the meeting to June 15th. This content directly relates to the procedures and announcements surrounding an Annual General Meeting (AGM). Although it mentions that related documents (like proxy forms) are available, the primary focus is the meeting logistics and rescheduling, making 'AGM Information' (AGM-R) the most appropriate classification, rather than a general 'Report Publication Announcement' (RPA) or 'Proxy Solicitation' (PSI), as it is a direct communication about the meeting status itself.
2023-06-02 English
Nicox : Assemblée Générale Ordinaire 2023
AGM Information Classification · 98% confidence The document is titled "Communiqué de presse" (Press Release) and specifically concerns the "Assemblée Générale Ordinaire 2023" (Annual General Meeting 2023). It announces that the meeting scheduled for June 1st failed to meet quorum and calls for a second meeting on June 15th. This document is an official announcement related to the scheduling and procedures for the Annual General Meeting. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, and in this case, the announcement of the rescheduled meeting itself.
2023-06-02 French
Monthly Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document explicitly states it is a 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' as of May 31, 2023, referencing French commercial code and AMF regulations. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure changes or mandatory periodic reporting. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals directly with the composition of the share capital and voting rights, it most closely aligns with a mandatory regulatory disclosure concerning share structure. Given the options, 'Share Issue/Capital Change' (SHA) covers capital structure updates, but this is a recurring disclosure of the *current* count, not an announcement of a change event. 'Regulatory Filings' (RNS) is the best fit for mandatory, periodic, non-financial disclosures that don't fit other specific categories like DIRS or DIV, especially when referencing specific regulatory articles (L.233-8 II of the Code de Commerce). However, since the content is purely about the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is a strong candidate if the intent is to track capital base changes. Given the context of mandatory monthly reporting on the capital base, RNS serves as the most appropriate general regulatory filing category when a more specific 'Capital Base Status Report' code is unavailable. I will select RNS as the most accurate fallback for this specific, recurring regulatory disclosure.
2023-06-01 English
PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF regulations) and provides a snapshot of the total shares and voting rights as of May 31, 2023. This type of regular disclosure regarding share capital and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the capital structure, although it is a recurring monthly disclosure rather than a one-time change announcement. However, given the nature of mandatory periodic disclosure of share count, and the lack of a specific 'Share Capital Disclosure' code, 'SHA' is the most appropriate classification for this capital structure update.
2023-06-01 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.